News | Cardiovascular Surgery | May 23, 2017

Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies

Study finds process could increase access to transplantation for patients at high immunological risk

Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies

May 23, 2017 — The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research presented at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure, April 29-May 2 in Paris, France. The breakthrough came on the 50th anniversary of heart transplantation.

Before heart transplantation, the serum of heart transplant candidates is tested for levels of anti-human leukocyte antigen (HLA) which could bind to donor HLA antigens and cause rejection of the organ. At the time of transplantation, a virtual crossmatch is conducted to determine if the patient’s anti-HLA antibodies are directed against the donor’s specific HLA antigen – if yes, they are called donor specific anti-HLA antibody (DSA).

“Most centers do not perform heart transplantation in patients with a high DSA level since the risk of antibody-mediated rejection is high, particularly hyper-acute rejection,” said lead author Guillaume Coutance, a cardiologist at Pitié-Salpêtrière Hospital in Paris, France. “Patients then have to wait for a donor with different HLA antigens.”

To reduce the chance of rejection in these patients at high immunological risk, in 2009 Pitié-Salpêtrière Hospital began a desensitization program. The current study analyzed the impact of the program on survival after heart transplantations performed during 2009 to 2015.

The type of desensitization patients receive depends on their DSA level, which is measured by mean fluorescence intensity (MFI). An MFI between 500 and 1,000 is considered low DSA and an MFI above 1,000 is considered high DSA. All patients receive anti-thymocyte globulins and conventional immunosuppressive therapy (calcineurin inhibitors, mycophenolate mofetil, and corticosteroids).

On top of this, patients with low DSA levels receive intravenous immunoglobulins. Patients with high DSA levels are treated with plasmapheresis before and after transplantation, followed by intravenous immunoglobulins after the complete cycle of plasmapheresis.

The study included 523 patients who were 50 years old on average and 77 percent were men. Nearly half (46 percent) of patients had no DSA, 17 percent had low DSA and 37 percent had high DSA levels. Patients were followed-up for an average of 3.7 years and survival was compared between the three groups.

Compared to patients with no or low DSA, those with high DSA were more often younger, female and had a ventricular assist device. The length of survival after transplantation was similar between the three groups, even after adjustment for age, sex and having a ventricular assist device before transplantation. Survival at one year and at the end of follow-up was 79 percent and 73 percent for those with no DSA, 80 percent and 72 percent in patients with low DSA, and 84 percent and 76 percent in patients with high DSA levels, respectively (p=0.85).

Antibody-mediated rejections were more common in patients with high DSA levels (27 percent versus 6 percent in patients with no DSA). These rejections occurred early (a median of 28 days after transplantation) in patients with high DSA levels but they had no impact on survival and could be treated. Patients with high DSA levels had more bleeding complications due to perioperative plasmapheresis.

Coutance said, “By desensitizing patient’s antibodies, those with high immunological risk experience similar survival to patients without DSA. Pre- and post-operative plasmapheresis results in a dramatic drop in DSA levels, which reduces the risk of hyper-acute rejections and early antibody-mediated rejections. Intravenous immunoglobulins will neutralize DSA for weeks.”

“Despite this regimen, antibody-mediated rejections were frequent but they were not associated with poor outcomes,” added Coutance. “Two factors might explain these good results: early diagnosis of rejection with repetitive routine biopsies, and aggressive treatment of rejections with plasmapheresis and intravenous immunoglobulins even in subclinical rejections. The increased bleeding risk is explained by the loss of coagulation factors during plasmapheresis which is important but does not seem to impact survival.”

He concluded, “This desensitization program could shorten waiting times and increase access to transplantation for patients at high immunological risk. However, it will probably not increase the number of transplantations since donor shortage is the limiting factor.”

For more information: www.escardio.org

Related Content

CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Overlay Init